How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
Read more: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
Variational AI – Emerging Company of the Year
Read more: Variational AI – Emerging Company of the Year27th Annual LSBC Award – Awards Video – Emerging Company of the Year -Biotech: Variational AI Read More about Variational AI – Emerging Company of the Year
Variational at Discovery on Target 2025
Read more: Variational at Discovery on Target 2025Variational is thrilled to be a part of Discovery on Target 2025, the top conference focused on novel drug targets and emerging discovery technologies. Our Head of Drug Discovery, Peter… Read More about Variational at Discovery on Target 2025
Variational at BIO-Europe 2025
Read more: Variational at BIO-Europe 2025We are pleased to share that Variational will be attending BIO-Europe 2025, Europe’s leading biopharma partnering event. We’ll be there to network with industry leaders, explore strategic partners, and showcase… Read More about Variational at BIO-Europe 2025
Variational Will Be at BioJapan 2025
Read more: Variational Will Be at BioJapan 2025Variational is excited to announce that we will be participating in BioJapan 2025, Asia’s premier bio-industry partnering event. We’ll be on site to meet partners, explore collaboration opportunities, and share… Read More about Variational Will Be at BioJapan 2025
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
Read more: Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug DiscoveryNew funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies Read More about Variational AI Announces Oversubscribed .5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Read more: Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug DiscoveryImmuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs. Read More about Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Variational AI and Rakovina announce Collaboration
Read more: Variational AI and Rakovina announce CollaborationRakovina announces potential multi-target engagement with Variational AI focused on DNA Damage Repair (DDR) Read More about Variational AI and Rakovina announce Collaboration
Variational AI announces generative AI project with Merck
Read more: Variational AI announces generative AI project with MerckVariational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. Read More about Variational AI announces generative AI project with Merck
Variational AI Makes Prestigious Additions to Scientific Advisory Board
Read more: Variational AI Makes Prestigious Additions to Scientific Advisory BoardVariational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced that it… Read More about Variational AI Makes Prestigious Additions to Scientific Advisory Board
